| For Practicing Oncologists |
  See all
 | Articles: Pharmacology/Therapy |
Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis
JAMA, 11/21/08
 | | Sponsor |
Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)
Journal of Clinical Oncology, 11/21/08
Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL study
Journal of Clinical Oncology, 11/21/08
Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402
Journal of Clinical Oncology, 11/21/08
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non–small-cell lung cancer
Journal of Clinical Oncology, 11/21/08
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206
Journal of Clinical Oncology, 11/21/08
Phase I/II study of ipilimumab for patients with metastatic melanoma
Journal of Clinical Oncology, 11/21/08
Effect of BRCA1 haplotype on survival of non-small cell lung cancer patients treated with platinum-based chemotherapy
Journal of Clinical Oncology, 11/21/08
Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials
Journal of Clinical Oncology, 11/21/08
American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of chemotherapy and radiation therapy protectants
Journal of Clinical Oncology, 11/21/08
|
|
Receive daily email updates on Pharmacology/Therapy
|
|
Indexed Journals: Journal of Clinical Oncology, Cancer Research, Annals Oncology
more...
|
250 Available Pages
 |
 |
| Sponsor |
|
|
Read a Different Specialty |
|
|
|
|
|
Profession Index
|
|
|
|
|
|
|
 |
| Sponsor |
|
|
| Sponsor |
|
